Alterity Therapeutics Limited
PRNAF
$0.0101
$0.0065180.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -15.53% | -13.55% | 36.54% | 33.19% | -21.05% |
| Total Revenue | -15.53% | -13.55% | 36.54% | 33.19% | -21.05% |
| Cost of Revenue | -34.49% | -32.81% | -7.42% | -9.60% | -39.92% |
| Gross Profit | -14.51% | -12.51% | 40.48% | 37.00% | -19.69% |
| SG&A Expenses | 60.58% | 64.34% | 20.38% | 17.41% | -27.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,433.33% | 1,475.00% | -61.54% | -61.54% | -85.71% |
| Total Operating Expenses | 7.33% | 9.84% | 91.58% | 86.85% | -21.62% |
| Operating Income | -13.88% | -16.55% | -105.06% | -100.00% | 21.78% |
| Income Before Tax | -10.22% | -12.80% | -114.77% | -109.46% | 18.67% |
| Income Tax Expenses | -- | -- | 7,500.00% | 7,500.00% | -- |
| Earnings from Continuing Operations | -10.22% | -12.80% | -115.53% | -110.22% | 19.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.22% | -12.80% | -115.53% | -110.22% | 19.72% |
| EBIT | -13.88% | -16.55% | -105.06% | -100.00% | 21.78% |
| EBITDA | -13.95% | -16.61% | -105.39% | -100.32% | 21.81% |
| EPS Basic | 50.00% | 44.44% | -12.50% | -12.50% | 27.27% |
| Normalized Basic EPS | 40.00% | 40.00% | 0.00% | 0.00% | 28.57% |
| EPS Diluted | 37.50% | 44.44% | -12.50% | -12.50% | 27.27% |
| Normalized Diluted EPS | 40.00% | 40.00% | 0.00% | 0.00% | 28.57% |
| Average Basic Shares Outstanding | 112.26% | 112.26% | 96.21% | 96.21% | 3.78% |
| Average Diluted Shares Outstanding | 112.26% | 112.26% | 96.21% | 96.21% | 3.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
